摘要
血管生成抑制因子对于调控肿瘤的生物学行为和肿瘤的治疗方面具有重要的作用。血管生成受正、负调控因子的双重作用,目前发现的与肝细胞癌(hepatocellularcarcinoma,HCC)有关的血管生成抑制因子有血管生成抑制素(AS)、内皮抑素(ES)、干扰素(IFN)、血小板反应素(TSP)、组织金属蛋白酶抑制剂(TIMP)、转化生长因子β1(TGFβ1)、白细胞介素12(IL12)、肿瘤坏死因子(TNF)、血小板因子4(PE4)及纤溶酶原抑制因子(PAI)等。其作用机制为:抑制内皮细胞的分裂和迁移,降低内皮细胞的活性,促进内皮细胞的凋亡或直接杀伤内皮细胞,干扰基底膜与内皮细胞的相互作用,抑制蛋白水解反应和内皮细胞的黏附运动,下调各种促血管生成因子的表达等。这些因子具有抗HCC血管生成治疗药物的潜在意义。
Angioinhibitory factors play an important role in biological behavior and treatment of tumours. Whether anglogenesis present in tumor or not is regulated by both angiogenic and angioinhibitory factors, and some hepatocellular carcinoma （HCC） related angioinhibitory factors at present include： angiostatin （ AS）, endostatin （ ES）, interferon （ IFN）, thrombospondin （TSP）, tissue inhibitor of MMP （TIMP）, transforming growth factor-β1 （TGFβ1）, interleukin-12 （IL-12）, tumor necrosis factor （TNF）, platelet factor 4 （PF4） and plasminogen activator inhibitor （PAI）. These factors can inhibit the division and migration of endothelial cells, decrease the cell activity, kill the endothelial cells or promote the cell apoptosis. On the other hand, they can also act on the interaction of endothelial cells and extracellular matrix such as protein hydrolysis and cell adhesion, and down-regulate the expressions of some angiogenic factors. These factors have the potential value as anti-angiogenesis drug for HCC.
出处
《肿瘤防治杂志》
2005年第17期1350-1354,共5页
China Journal of Cancer Prevention and Treatment
关键词
癌
肝细胞
血管生长抑制因子
新生血管化
病理性
综述文献
carcinoma, hepatocellular
angioinhibitory factor
neovascularization, pathologic
review literature
